JP4283474B2 - ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 - Google Patents

ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 Download PDF

Info

Publication number
JP4283474B2
JP4283474B2 JP2001505952A JP2001505952A JP4283474B2 JP 4283474 B2 JP4283474 B2 JP 4283474B2 JP 2001505952 A JP2001505952 A JP 2001505952A JP 2001505952 A JP2001505952 A JP 2001505952A JP 4283474 B2 JP4283474 B2 JP 4283474B2
Authority
JP
Japan
Prior art keywords
antibody
erbb2
cells
antibodies
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001505952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503366A5 (enExample
JP2003503366A (ja
Inventor
アダムス，カメリア，ダブリュ．
プレスタ，レオナード，ジー．
スリューコースキー，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4283474(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2003503366A publication Critical patent/JP2003503366A/ja
Publication of JP2003503366A5 publication Critical patent/JP2003503366A5/ja
Application granted granted Critical
Publication of JP4283474B2 publication Critical patent/JP4283474B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicinal Preparation (AREA)
JP2001505952A 1999-06-25 2000-06-23 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療 Expired - Lifetime JP4283474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
US60/141,316 1999-06-25
PCT/US2000/017366 WO2001000245A2 (en) 1999-06-25 2000-06-23 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008333670A Division JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Publications (3)

Publication Number Publication Date
JP2003503366A JP2003503366A (ja) 2003-01-28
JP2003503366A5 JP2003503366A5 (enExample) 2008-06-05
JP4283474B2 true JP4283474B2 (ja) 2009-06-24

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001505952A Expired - Lifetime JP4283474B2 (ja) 1999-06-25 2000-06-23 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療
JP2008333670A Withdrawn JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008333670A Withdrawn JP2009142280A (ja) 1999-06-25 2008-12-26 ヒト化抗−ＥｒｂＢ２抗体及び抗−ＥｒｂＢ２抗体を用いた治療

Country Status (32)

Country Link
EP (2) EP1189641B1 (enExample)
JP (2) JP4283474B2 (enExample)
KR (2) KR100850389B1 (enExample)
CN (4) CN101121021B (enExample)
AR (1) AR024464A1 (enExample)
AT (2) AT500848B1 (enExample)
AU (2) AU784045B2 (enExample)
BE (1) BE2013C020I2 (enExample)
BR (2) BR122014028365B8 (enExample)
CA (2) CA2376596C (enExample)
CH (1) CH694589A5 (enExample)
CY (2) CY1109525T1 (enExample)
CZ (1) CZ299702B6 (enExample)
DE (2) DE60042648D1 (enExample)
DK (1) DK1189641T5 (enExample)
ES (1) ES2329437T3 (enExample)
FR (1) FR13C0016I2 (enExample)
GB (1) GB2368796B (enExample)
GE (1) GEP20104998B (enExample)
HU (1) HU226742B1 (enExample)
IL (3) IL146954A0 (enExample)
LU (1) LU92164I2 (enExample)
MX (1) MXPA01013458A (enExample)
NO (3) NO328377B1 (enExample)
NZ (2) NZ531426A (enExample)
PL (2) PL204629B1 (enExample)
PT (1) PT1189641E (enExample)
RU (2) RU2270029C2 (enExample)
SI (3) SI2283867T1 (enExample)
TR (1) TR200103756T2 (enExample)
WO (1) WO2001000245A2 (enExample)
ZA (2) ZA200109786B (enExample)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
AT500848B1 (de) * 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012196B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
PL202369B1 (pl) 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
CH696871A5 (de) * 2001-10-26 2008-01-15 Altarex Medical Corp Verwendung eines chemotherapeutischen Arzneimittels und einer Zusammensetzung, die ein Bindemittel umfasst, zur Herstellung eines Medikamentes zur Krankheitsbehandlung.
WO2003087338A2 (en) * 2002-04-11 2003-10-23 Amgen, Inc. Her-2 receptor tyrosine kinase molecules and uses thereof
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
MXPA05000778A (es) 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
JP4959136B2 (ja) * 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
WO2005003325A2 (en) * 2003-03-11 2005-01-13 Dana Farber Cancer Institute Inhibition of viral pathogenesis
EP1631590B1 (en) * 2003-04-23 2011-07-27 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
JP2007504164A (ja) * 2003-08-29 2007-03-01 セダーズ−シナイ メディカル センター ＰＰＡＲ−γ経路およびＨＥＲ−キナーゼ軸の調節に基づく癌および他の生理学的状態の処置のための組成物および方法
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
MXPA06006009A (es) * 2003-11-28 2006-09-04 Mitra Medical Technology Ab Direccionamiento de antigenos erb.
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
HRP20141111T1 (hr) 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) * 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MX2008015581A (es) * 2006-06-05 2008-12-17 Genentech Inc Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
ES2392630T3 (es) 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
NZ601022A (en) * 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2899541A1 (en) * 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
KR20100056438A (ko) * 2007-06-18 2010-05-27 메디뮨 엘엘씨 ＥｐｈＡ2 및 ＥｒｂＢ2를 발현하는 세포의 상승적 치료 방법
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
CN105315323A (zh) 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009068631A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
JP2011517555A (ja) 2008-03-14 2011-06-16 ジェネンテック， インコーポレイテッド 薬剤耐性に関連する遺伝的変異
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
HUE031902T2 (en) 2008-05-23 2017-08-28 Siwa Corp Procedures and Preparations to Promote Regeneration
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
MX336476B (es) * 2009-08-15 2016-01-20 Genentech Inc Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2493929B1 (en) * 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr antibodies and their uses
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
PL2532365T3 (pl) * 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
BR112012029866A2 (pt) 2010-06-03 2017-03-07 Genentech Inc método para a determinação da presença de uma proteína steap-1
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
US20140162317A1 (en) 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
WO2012085113A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Binding agent
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CA2825605C (en) 2011-01-31 2019-05-07 Novartis Ag Heterocyclic derivatives
US9133270B2 (en) 2011-03-08 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody-like proteins for therapeutic and diagnostic use
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
RU2014135224A (ru) 2012-01-31 2016-03-27 Смитклайн Бичем (Корк) Лимитед Способ лечения злокачественных опухолей
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
EP2943484B1 (en) 2013-01-10 2017-10-25 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
EP3072907B1 (en) 2013-11-19 2019-02-20 Remegen, Ltd Anti-her2 antibody and conjugate thereof
EP4570318A3 (en) 2013-11-27 2025-10-15 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
HRP20190431T1 (hr) 2014-01-31 2019-04-19 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
PL3116999T3 (pl) 2014-03-14 2021-12-27 F.Hoffmann-La Roche Ag Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
CA2961603C (en) 2014-09-19 2021-07-13 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
AU2016262168B2 (en) * 2015-05-13 2022-06-23 Zymeworks Bc Inc. Antigen-binding constructs targeting HER2
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
BR112018007422A2 (pt) * 2015-10-13 2018-10-30 Siwa Corp anticorpos anti-age e métodos de uso dos mesmos
KR20180073674A (ko) 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US20190256608A1 (en) 2015-12-01 2019-08-22 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
KR102786111B1 (ko) 2016-02-19 2025-03-26 시와 코퍼레이션 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
SG11201810032PA (en) * 2016-05-12 2018-12-28 Agency Science Tech & Res Anti-erbb-2 antibodies and uses thereof
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
AU2017341000B2 (en) 2016-10-07 2024-11-28 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
KR102646046B1 (ko) * 2017-01-06 2024-03-08 바이오션, 인코포레이티드 Erbb2 항체 및 이의 용도
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
EP3609923A1 (en) 2017-04-13 2020-02-19 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
KR20200044044A (ko) 2017-08-23 2020-04-28 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
SG11202011243XA (en) 2018-05-28 2020-12-30 Daiichi Sankyo Co Ltd Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
BR112021001194A2 (pt) 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
EP3831412A4 (en) 2018-07-31 2022-04-27 Daiichi Sankyo Company, Limited TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE
TW202019487A (zh) 2018-08-06 2020-06-01 日商第一三共股份有限公司 抗體-藥物結合物及微管蛋白抑制劑之組合
EP3842546A4 (en) 2018-08-23 2022-06-29 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
AU2019349934B2 (en) 2018-09-25 2024-12-05 Absci Corporation Protein purification methods
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
SG11202106248XA (en) 2018-12-11 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate with parp inhibitor
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
EP4096718A1 (en) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
IL299368A (en) 2020-06-24 2023-02-01 Astrazeneca Uk Ltd A combination of an antibody-drug conjugate and an ATR inhibitor
US20230233540A1 (en) 2020-06-24 2023-07-27 Astrazeneca Uk Limited Combination of antibody-drug conjugate and cdk9 inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
KR20230042055A (ko) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
BR112023006337A2 (pt) 2020-10-09 2023-05-09 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
KR20230106645A (ko) 2020-11-11 2023-07-13 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 항 SIRPα 항체의 조합
KR20240113514A (ko) 2021-11-30 2024-07-22 다이이찌 산쿄 가부시키가이샤 프로테아제 분해성 마스크 항체
JP2025503511A (ja) 2021-12-28 2025-02-04 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
TW202400650A (zh) 2022-05-11 2024-01-01 日商第一三共股份有限公司 抗體與cd47抑制劑之組合
CA3262449A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A BISPECIFIC CHECKPOINT INHIBITOR
WO2025005240A1 (ja) 2023-06-30 2025-01-02 第一三共株式会社 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法
JPWO2025047983A1 (enExample) 2023-08-31 2025-03-06
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
CA2207869A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
JP4214537B2 (ja) * 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
EP0931147A1 (en) * 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
AT500848B1 (de) * 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
BRPI0012196B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
PL202369B1 (pl) * 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało

Also Published As

Publication number Publication date
KR100797308B1 (ko) 2008-01-23
CN101518653B (zh) 2015-08-19
ATE437655T1 (de) 2009-08-15
BR0012198A (pt) 2002-04-02
IL197359A0 (en) 2011-07-31
BR122014028365B8 (pt) 2021-07-06
CN101518653A (zh) 2009-09-02
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
GB2368796A (en) 2002-05-15
WO2001000245A3 (en) 2001-10-25
EP1189641A2 (en) 2002-03-27
SI2283866T1 (sl) 2015-07-31
GEP20104998B (en) 2010-06-10
RU2270029C2 (ru) 2006-02-20
HU226742B1 (en) 2009-08-28
GB0200506D0 (en) 2002-02-27
BRPI0012198B8 (pt) 2021-05-25
CN1370082A (zh) 2002-09-18
CN101121750A (zh) 2008-02-13
CN101121021B (zh) 2011-12-07
FR13C0016I1 (enExample) 2013-04-12
ES2329437T3 (es) 2009-11-26
KR100850389B1 (ko) 2008-08-04
EP2112167A2 (en) 2009-10-28
SI1189641T1 (sl) 2009-12-31
SI2283867T1 (sl) 2014-07-31
NO20091792L (no) 2002-02-25
CZ20014596A3 (cs) 2003-02-12
KR20070094993A (ko) 2007-09-27
CY2013010I1 (el) 2015-08-05
NZ531426A (en) 2005-10-28
NO336040B1 (no) 2015-04-27
CZ299702B6 (cs) 2008-10-22
BRPI0012198B1 (pt) 2016-12-20
CN101121021A (zh) 2008-02-13
CA2376596C (en) 2009-10-06
HUP0201695A2 (en) 2002-09-28
AU2005242195A1 (en) 2006-01-12
KR20020068264A (ko) 2002-08-27
DE10084743T1 (de) 2002-08-14
ZA200109786B (en) 2002-11-28
AU5763200A (en) 2001-01-31
AR024464A1 (es) 2002-10-02
CN100340575C (zh) 2007-10-03
NO20016329D0 (no) 2001-12-21
NO2013005I1 (no) 2013-04-02
PL203326B1 (pl) 2009-09-30
DK1189641T5 (da) 2011-04-11
BE2013C020I2 (enExample) 2019-08-21
CA2376596A1 (en) 2001-01-04
ZA200110263B (en) 2003-02-26
TR200103756T2 (tr) 2002-06-21
EP1189641B1 (en) 2009-07-29
DK1189641T3 (da) 2009-11-16
JP2009142280A (ja) 2009-07-02
BR122014028365B1 (pt) 2020-01-28
NZ516830A (en) 2004-07-30
AU784045B2 (en) 2006-01-19
AT500848B1 (de) 2008-01-15
AU2005242195B2 (en) 2009-06-11
PL352321A1 (en) 2003-08-11
LU92164I2 (fr) 2013-05-07
DE60042648D1 (de) 2009-09-10
HK1044888A1 (en) 2002-11-08
RU2005132788A (ru) 2007-04-27
CA2727172A1 (en) 2001-01-04
RU2430739C9 (ru) 2015-12-20
RU2430739C2 (ru) 2011-10-10
JP2003503366A (ja) 2003-01-28
CH694589A5 (de) 2005-04-15
AT500848A1 (de) 2006-04-15
PL204629B1 (pl) 2010-01-29
WO2001000245A2 (en) 2001-01-04
FR13C0016I2 (fr) 2014-05-16
PT1189641E (pt) 2009-11-04
IL146954A (en) 2009-09-22
HUP0201695A3 (en) 2005-06-28
CY1109525T1 (el) 2014-08-13
NO2013005I2 (no) 2013-03-12
IL146954A0 (en) 2002-08-14
EP2112167A3 (en) 2010-12-22
MXPA01013458A (es) 2002-07-30
GB2368796B (en) 2004-08-04
CY2013010I2 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
JP4969440B2 (ja) 疼痛治療のためのＥｒｂＢアンタゴニスト
CN101121021B (zh) 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
US6949245B1 (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20070184055A1 (en) Treatment with anti-erbb2 antibodies
US20040013667A1 (en) Treatment with anti-ErbB2 antibodies
JP2003503361A (ja) 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
JP2006516117A (ja) 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
HK1044888B (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
HK1130502A (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080415

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080724

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090319

R150 Certificate of patent or registration of utility model

Ref document number: 4283474

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120327

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120327

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130327

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130327

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140327

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term